Login to Your Account



Syntimmune progress triggers $10M from Apple Tree, Baxalta

By Michael Fitzhugh
Staff Writer

Tuesday, March 22, 2016

Syntimmune Inc., a company developing a portfolio of treatments for immunoglobulin G-mediated autoimmune diseases based on neonatal Fc receptor (FcRn) biology, has triggered a $10 million tranche of the company's committed $26 million series A financing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription